IGC Pharma (IGC) Other Non-Current Assets (2011 - 2026)
IGC Pharma (IGC) posted quarterly Other Non-Current Assets of $659000.0 for Q1 2026, down 3.23% year-over-year from $681000.0 in Q1 2025, and down 1.49% quarter-over-quarter from $669000.0 in Q4 2025.
IGC Pharma (IGC) Other Non-Current Assets (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Other Non-Current Assets for 16 consecutive years, with $659000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 3.23% year-over-year to $659000.0; the TTM figure through Mar 2026 stood at $659000.0 (down 3.23% YoY), while the FY2026 annual figure was $659000.0, down 3.23% from the prior year.
- Other Non-Current Assets slipped to $659000.0 in Q1 2026 per IGC's latest filing, from $669000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q4 2022 and bottomed at $2000.0 in Q3 2024.
- Historically, Other Non-Current Assets has averaged $580000.0 across 5 years, with a median of $680000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 97.37% — and 2025, when it jumped 33500.0%.
- IGC Pharma's Other Non-Current Assets stood at $1.0 million in 2022, then plunged by 97.37% to $27000.0 in 2023, then surged by 592.59% to $187000.0 in 2024, then surged by 257.75% to $669000.0 in 2025, then retreated by 1.49% to $659000.0 in 2026.
- Business Quant data shows IGC's Other Non-Current Assets at $659000.0 in Q1 2026, $669000.0 in Q4 2025, and $672000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 659,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 659,000.00 |
| Dec 31, 2025 | 669,000.00 |
| Sep 30, 2025 | 672,000.00 |
| Jun 30, 2025 | 680,000.00 |
| Mar 31, 2025 | 681,000.00 |
| Dec 31, 2024 | 187,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 688,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 26,000.00 |
| Jun 30, 2023 | 1.02 Mn |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 950,000.00 |
| Jun 30, 2022 | 922,000.00 |
| Mar 31, 2022 | 937,000.00 |
| Sep 30, 2021 | 611,000.00 |
| Jun 30, 2021 | 596,000.00 |
| Mar 31, 2021 | 603,000.00 |